Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen

We aimed to investigate the long-term prognosis and prognostic factors of T-cell lymphoblastic lymphoma (T-LBL) patients who received dose-adjusted Berlin–Frankfurt–Münster (BFM)-90 regimen as first-line therapy in our center. A total of 145 T-LBL patients who underwent first-line dose-adjusted BFM-...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Hui, Mi, Lan, Qi, Fei, Wang, Xing, Ye, Yingying, Li, Miaomiao, Wang, Dedao, Ding, Ning, Wang, Xiaogan, Song, Yuqin, Zhu, Jun, Xie, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037275/
https://www.ncbi.nlm.nih.gov/pubmed/35400665
http://dx.doi.org/10.18632/aging.204008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037275/
https://www.ncbi.nlm.nih.gov/pubmed/35400665
http://dx.doi.org/10.18632/aging.204008

Ejemplares similares